In French hospitals, a new kind of demand has been appearing in consultation schedules. Patients seeking treatment for obesity have increasingly asked about medicines that were once associated primarily with diabetes care.
Since June 15, France has reimbursed the anti-obesity medicines Wegovy and Mounjaro for certain eligible patients. The reimbursement rate was set at 65%, but access remains subject to strict medical conditions.
The two medicines contain semaglutide and tirzepatide respectively. Both belong to a class of treatments that influence hormonal pathways involved in blood-sugar regulation and appetite, helping some patients achieve substantial weight loss.
The French reimbursement framework does not apply to everyone seeking weight-loss treatment. According to the rules reported by Le Monde, reimbursement is limited primarily to patients with severe or massive obesity meeting specified body-mass-index thresholds and, in some cases, additional medical conditions.
The first reimbursed prescription also requires specialized medical involvement. Initial prescriptions are reserved for certain specialized healthcare settings, including obesity centers and university hospitals, while general practitioners can participate in continuing treatment after specialist initiation.
The change has created new pressure on specialized centers. At Paris's Pitié-Salpêtrière Hospital, around 250 requests for first consultations were reported within one week as reimbursement approached, illustrating the level of interest surrounding the medicines.
Cost is another part of the story. Before reimbursement, patients could pay around €300 per month for injectable treatment, depending on the medicine, dose, and pharmacy. The introduction of partial reimbursement therefore changed the financial equation for eligible patients.
The medicines have also attracted attention beyond hospitals. Their growing popularity has created a broader market involving pharmaceutical companies, pharmacies, doctors, and digital platforms, while health authorities continue to emphasize that the treatments should be used within appropriate medical frameworks.
In August, the pharmaceutical market was already moving toward another development: oral versions of anti-obesity medicines. Le Monde reported that Novo Nordisk and Eli Lilly were preparing wider international expansion of tablet-based treatments, following the rapid uptake of oral products in some markets.
For France, the arrival of these medicines represents more than another category of prescription drugs. It brings together questions of medical eligibility, long-term treatment, healthcare spending, specialist capacity, and the changing understanding of obesity as a chronic health condition.
AI Image Disclaimer The illustrations were generated using AI for conceptual purposes and are not photographs of actual patients, doctors, or hospitals.
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
